US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by Philogen S.p.A.

News headline image
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus
From Philogen S.p.A.
Via GlobeNewswire
Tickers BMY
News headline image
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
From Philogen S.p.A.
Via GlobeNewswire
Tickers BSE
News headline image
Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS
From Philogen S.p.A.
Via AccessWire
Topics Derivatives
News headline image
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
From Philogen S.p.A.
Via AccessWire
News headline image
Philogen Announces Participation to the 10th World Congress of Melanoma
From Philogen S.p.A.
Via AccessWire